卡铂或顺铂经动脉灌注化疗晚期非小细胞肺癌的临床观察

目的 探讨卡铂经动脉灌注化疗晚期非小细胞肺癌的临床应用价值.方法 52例经病理学或细胞学证实为晚期非小细胞肺癌的患者,根据灌注化疗药物是否包括卡铂（Carbo）或顺铂（CDDP）分为Carbo组和CDDP组.观察两组经动脉灌注化疗后的疗效及毒副反应,并用x2检验比较两组的疗效及毒副反应差别.结果 52例患者中,Carbo组27例,CDDP组25例.无一例完全缓解.Carbo组部分缓解（PR）15例,稳定8例,进展4例.有效率（PR）为55.6%.CDDP组部分缓解（PR）15例,稳定7例,进展3例.有效率（PR）为60%.二者疗效差别无统计学意义（P＞0.05）.不良反应包括骨髓抑制及胃肠道反应,两组间无统计学差异（P＞0.05）.结论 与顺铂比较,卡铂经动脉灌注给药治疗晚期非小细胞肺癌没有疗效及毒副反应方面的优势.我们主张经动脉灌注化疗非小细胞肺癌仍应选用顺铂作为铂类联合化疗药物.

Clinical observation of trans-artery infusion chemotherapy with carboplatin or cisplatin in advanced non-small-cell lung cancer

Objective To evaluate the effect of trans-artery infusion chemotherapy with carboplatin in advanced non-small-cell lung cancer. Methods Fifty-two patients with advanced non-small-cell lung cancer pathologically confirmed were treated by trans-artery chemotherapy. They were divided into Carbo group and CDDP group according to anti-cancer drug. The effectiveness of treatment and complication were observed respectively. x 2 test was applied for statistical analysis. Results There were 27 patients in Carbo group and 25 in CDDP group. In Carbo group, 15 had partial remission (PR), 8 were stable (S) and progression (P) was observed in 4. A responsive rate of 55.6% was obtained. In CDDP group, 15 cases showed tumor partial remission (PR), 7 were stable (S) and 3 were progression (P). The responsive rate was 60%. There was no statistical significance between them (P>0.05). There was no statistical significance in incidence rate of myelosuppression, nausea and vomiting between Carbo group and CDDP group (P>0.05). Conclusion Compared with CDDP, trans-artery infusion chemotherapy with Carbo has no better therapeutic effect and no less adverse effects. We maintain CDDP as anti-cancer drug when we perform arterial infusion chemotherapy of advanced non-small-cell lung cancer.